This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

12 Aug 2011

Boehringer Signs Licensing Agreement with ProBioGen for Technology Combination

Boehringer Ingelheim and ProBioGen AG signed a licensing agreement to enhance activity of antibodies.

Boehringer Ingelheim and ProBioGen AG announced Wednesday they have signed a non-exclusive licensing agreement under which Boehringer’s Contract Manufacturing Business will apply ProBioGen’s GlymaxX technology to enhance ADCC (Antibody-Dependent Cell-Mediated Cytotoxicity) activity of antibodies.


According to the company, ProBioGen’s GlymaxX technology can be integrated into Boehringer’s high expression CHO-based BI-HEX system. Both companies will jointly market the technology and offer it to customers royalty free. ?


"We are very pleased that Boehringer Ingelheim has decided to integrate our GlymaxX technology into their technology portfolio for customer and in-house projects. This is an additional milestone in our long-standing business relationship," said

Related News